Efficacy and safety of low-molecular-weight collagen peptides in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Introduction

Knee osteoarthritis (OA) is a common degenerative joint disease with limited safe, long-term treatment options. Nutritional interventions, such as low-molecular-weight collagen peptides (LMCP), have emerged as promising non-pharmacological strategies for joint health. However, clinical evidence is insufficient. Therefore, we aimed to assess the efficacy and safety of LMCP supplementation in patients with knee OA.

Methods

In this double-blind, randomized, placebo-controlled trial, 80 adults aged 40-75 with Kellgren-Lawrence (KL) grade I or II OA received either 3,000 mg/day LMCP or a placebo for 180 days. Primary endpoint included changes in Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain scores. Secondary endpoints included visual analog sc

SUBMITTER: Park SY 

PROVIDER: S-EPMC12445226 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature